{"name":"Eupraxia Pharmaceuticals Inc.","slug":"eupraxia-pharmaceuticals-inc","ticker":"","exchange":"","domain":"eupraxia.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVGNaRjVGWElCRFhOcWViV3hpbUZrVURJNFE5M3FXcWljeWcyRFhzb2RNb3NBQXRmZHRsbzdpMUV5WVJQS0s2ZmNHdUxOZHZRRnY0Tm9jdUlHMHBMeUZIZ2RvSlNGaU9raEp0TnF5SXFIVW0teEtiTzdxTVFHN210VjZ4aUxUVF95SnVLVzBtbGh2ZEJEaHJqRzBraDJJaUtnbTdXRElCU3MyRE9CZEpqajRvWkhsblpOSXFtOWstT2hfTlk?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Eupraxia Pharmaceuticals (NASDAQ: EPRX) files 2025 Form 40-F with audited statements - Stock Titan","headline":"Eupraxia Pharmaceuticals (NASDAQ: EPRX) files 2025 Form 40-F with audited statements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNWThTWEcwVm1GM2ZzM2NsSDMyaVNDbVREenZvdzR2Z0Y3XzZYUDdGck1qX1ZUdWFxbnlaNVczdG1NcTJaTzJudGVOTjFfcVg1eEZzZWU4d0dBdUpoYzBnQnJNazFRYlBUUno5aHJhR2l1SjZpeTJMRHRmYm9NTzN4NkJETnFZbEVOaDFhWVkxUVh1ZC1GZGdLclZKazNLX0V2OTUtVjloVzBxVXVkaVFLRGl4Nk5ocE1BMGhSU0lpWG1xZGlrSFRUR0ttdTBtZTlWQ0dUOWFDYmF6QQ?oc=5","date":"2026-03-12","type":"earnings","source":"GlobeNewswire","summary":"Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - GlobeNewswire","headline":"Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQV3dFcWp0cFNUZXd2YUpPWFdXcUVuSldMX2lTZWs3OXZleFplZDd0MWZUSHZqTG5lTGpPZUlDNFZjX0J1SnhXNWJ3dHFMTm1DZmk1ZjQ2MllJa0wxYl94V05CUmFqbjEyd2FxTjFwa0FDQzBjR3BMSkh1TWowa0pOdjdlOXFaOU9IRU1aYmlFdjZ2Z2J5TTR0YXppRFVJUlFCSnBIMUVIeUtNRUJzVUY2Yk9LRlFmcE11cjZxemp0eWIxeDlrX0V5Wk9PZHREd0JuWU9EV2xhdXpWTnRNZVp0dERZbzNaRFE1emtSZW1LM2haNTRpWktXMjdPUWxmclg3dFBuTmRrR2VWa3lwV1VaeHBONkNkTUk?oc=5","date":"2026-02-19","type":"pipeline","source":"GlobeNewswire","summary":"Eupraxia Pharmaceuticals Announces Pricing of US$55 Million - GlobeNewswire","headline":"Eupraxia Pharmaceuticals Announces Pricing of US$55 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOZUxnWGM0TlVGRnJMMnN2SVJTS2I3QjVwZGxHODRWSi1UOVdFQU9pZDNzRy1qSXd5dzZ1WXJZN1pJZVZudlpiLU5JbTRLYXRzNjZZMWJnVTN3eTIzRWZaR1ZKOTBJaHpRU1JfSmRySEZRMXo5NnVscW1HeVhlX0thMHZueUpJaEpLWnI5UXIyS3FQeUVtTVF6U09ydk00WGU0SjhSaE5HdERfbnNLb2xwdHFyLXhDZUp4YTVka0M0LWtwbC1tLXdIMUJRNA?oc=5","date":"2026-02-18","type":"pipeline","source":"GlobeNewswire","summary":"Eupraxia Pharmaceuticals Announces Proposed Public Offering - GlobeNewswire","headline":"Eupraxia Pharmaceuticals Announces Proposed Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNS2VjcnQwcnpRd2piVE5oV3dqcnAtYmlQMGdPcE1ybHA2bTFRY2tYa1pzdGYxOTZDY1ZrYUxGN2FrVG5JeGljd1BGekhFeUJyT054R0JJQkJkS2Npb04wSkRPYlQtUjdELTctSDJPYUkzWEpPSUtkVDlSbUM5WFJNMDI4ZTZ2OU5mbF9Ja3VjR09NMWxGQlVQYzg1Qk5RYmIyQ3Z4emNxdkcyaGd4aHYtU3BYcGZiWUZlSWp4VThGazF3TklVSU5QQ2VKUTNWUmJoeTVjZktfMWVLU2w3c1hFMUUyNXFla3BPLTFNRGNiRVNmTHVpN3ZMMWNFRWRBbFlaMVZOc1NYN3FueHpUbF9HLTZYS182Q3h1azItcEt1OE0?oc=5","date":"2025-09-24","type":"pipeline","source":"GlobeNewswire","summary":"Eupraxia Pharmaceuticals Announces Closing of US$80.5 - GlobeNewswire","headline":"Eupraxia Pharmaceuticals Announces Closing of US$80.5","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQSC1aTjVUaWtuRkxBcUNpN2ZkUTJ5akVxakhLYnNOWHd4dnV0Zl9pSHhZYkxOQ0RfNU5MUm5Ddi14WmhMZm00bzAwcmdXOHdfZk1UQXVVbDYycFZyQmZCN1YzbGkyTHJfQy1DUVFmYnFvdEQtRGFGWjljZTloeGJfUDlWY3o0U1hDSnQ2S2p1aGVldEZrZ05xeHo0T0F3cElNa3RxdndJRmNzN0xlUU1WZERJWFhLeDVsOVlGejZ1UngwU19LMkZJLWRpczhRSXVxdHpZSFcxRGlvdlpiUkkzM0ZURS1rc3lRdV9QbzRuRzg?oc=5","date":"2024-10-31","type":"pipeline","source":"PR Newswire","summary":"Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - PR Newswire","headline":"Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}